There is no way Ginkgo Bioworks Holdings Inc (DNA) can keep these numbers up

With 27.06 million shares changed hands, the volume of the stock remained heavier than its average volume of 22.58 million shares. The 52-week range on DNA shows that it touched its highest point at $2.55 and its lowest point at $1.03 during that stretch. It currently has a 1-year price target of $1.97. Beta for the stock currently stands at 1.36.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DNA was down-trending over the past week, with a drop of -3.67%, but this was down by -18.60% over a month. Three-month performance dropped to -37.87% while six-month performance fell -41.99%. The stock lost -14.63% in the past year, while it has lost -37.87% so far this year. A look at the trailing 12-month EPS for DNA yields -0.46 with Next year EPS estimates of -0.27. For the next quarter, that number is -0.08. This implies an EPS growth rate of 30.58% for this year and 14.75% for next year.

Float and Shares Shorts:

At present, 1.53 billion DNA shares are outstanding with a float of 1.34 billion shares on hand for trading. On Mar 15, 2024, short shares totaled 262.24 million, which was 12.18% higher than short shares on Feb 15, 2024. In addition to XDNA as the firm’s Strategic CRISPR & Gene Editing, TNA serves as its Direxion Small Cap Bull 3X Shar.

Institutional Ownership:

Through their ownership of 83.72% of DNA’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DNA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.